A client with leukemia is receiving immunotherapy as part of their treatment plan. What is the primary purpose of immunotherapy in leukemia treatment?

A) This choice is incorrect because leukemia does not result from an overproduction of platelets. Leukemia involves an overproduction of abnormal white blood cells.

B) This choice is incorrect because leukemia is not caused by the body's immune system attacking healthy white blood cells. Instead, it involves the uncontrolled growth of abnormal white blood cells.

C) This choice is correct. Leukemia is characterized by genetic mutations in the bone marrow cells, particularly in the stem cells that produce white blood cells. These mutations lead to uncontrolled growth and proliferation of abnormal white blood cells, interfering with the normal production of other blood cells.

D) This choice is incorrect because an imbalance of red blood cells would not trigger the overproduction of white blood cells. Leukemia is specifically a disorder of white blood cell proliferation.

A) This choice is incorrect because the distinction between targeted therapy and chemotherapy is not based on whether the medications are derived from natural or synthetic sources.

B) This choice is correct. Targeted therapy is designed to selectively target leukemia cells, minimizing damage to healthy cells and reducing side effects compared to traditional chemotherapy, which affects both cancerous and healthy cells.

C) This choice is incorrect because the method of administration (hospitalization or outpatient) can vary for both targeted therapy and chemotherapy, depending on the specific drug and treatment plan.

D) This choice is incorrect because targeted therapy and chemotherapy are used in various stages of leukemia treatment, depending on the type and stage of the disease.